| アブストラクト | Aim: This retrospective chart review was designed to evaluate physician adherence to the prescribing information for fondaparinux regarding adjunctive anticoagulant use during percutaneous coronary intervention (PCI) in patients with an acute coronary syndrome (ACS). Methods and results: Medical record abstractors at each site obtained information regarding the use of fondaparinux and adjunctive anticoagulants during PCI. Physician adherence to fondaparinux prescribing information regarding the administration of an adjunctive anticoagulant during PCI was estimated using generalized estimating equations. This retrospective study, conducted in 2008-2010, included a total of 1056 patient records from 27 sites across 6 countries (Canada, France, Germany, Greece, Poland, and Sweden). Over 98% of patients had been treated with fondaparinux at the recommended 2.5 mg dose. Use of adjunctive anticoagulant during PCI was 97.5%, giving an adjusted adherence rate of 98.8% (95% confidence interval: 0.97-0.99), with 86.3% of patients receiving unfractionated heparin. Although the sub-group of patients with ST-elevation myocardial infarction who underwent primary PCI was too small to make a definitive conclusion, 70.4% of the 159 patients did not receive fondaparinux immediately prior to (<24 h) or during primary PCI, suggesting that their treating physicians may have been adherent to the prescribing information. Conclusion: Physician adherence to the prescribing information for adjunctive anticoagulation during PCI in patients with an ACS receiving fondaparinux was high. The results were consistent in each of the six countries and across patient sub-groups. |
|---|
| 投稿者 | Abell, Jill E; Laing, Shiona M; Barker, Tara C; Norry, Elliott C; Starzyk, Kathryn; Goodman, Shaun G; Dellborg, Mikael; Steg, P Gabriel; Giugliano, Robert P |
|---|
| 組織名 | Worldwide Epidemiology, GlaxoSmithKline Research and Development, 709 Swedeland;Road, King of Prussia, PA 19406, USA.;Metabolic Pathways and Cardiovascular Unit, GlaxoSmithKline Research and;Development, Stockley Park West, 1-3 Ironbridge Road, Uxbridge, Middlesex UB11;1BT, UK.;Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline Research and;Development, 1250 South Collegeville Road, Collegeville, PA 19426, USA.;Epidemiology, Quintiles, 201 Broadway, 5th Floor, Cambridge, MA 02139, USA.;Department of Medicine, Terrence Donnelly Heart Centre, St. Michael's Hospital,;University of Toronto, 160 College Street, Toronto, Ontario M5S 3E1, Canada.;Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska;Academy, University of Goteborg, Guldhedsgatan 10, S-41346?Goteborg, Sweden.;Departement Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and REmodeling),;Universite Paris-Diderot, Hopital Bichat Assistance Publique - Hopitaux de Paris,;46 rue Henri Huchard, Paris 75018, France.;Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard;Medical School, 75 Francis Street, Boston, MA 02115, USA. |
|---|
